Pedro Miguel Geraldes

Prix et distinctions

• (2020) New investigator Award. Arterial Hypertention Society of Quebec.
• (2017) Chercheur boursier Junior 2. Fonds de recherche du Québec.
• (2017) 2017 Young Investigator Award. FRQS CardioMetabolic, Diabetes and Obesity (CMDO) Network.
• (2012) Canada Research Chair Tier II (2012-2023). Canada Research Chairs.
• (2012) Chercheur boursier Junior 1. FRQS.
• (2011) Canadian Diabetes Association Scholar Award. Daibetes Canada.
• (2011) Young Scientist Scholar Award. FRQS.
• (2010) Best presentation. Montreal Research Diabetes Center.
• (2009) Advanved Postdoctoral Award. Juvenile Diabetes Research Foundation.
• (2009) Young Investigator Travel Grant Award. American Diabetes Association.
• (2007) Postdoctoral Award. Juvenile Diabetes Research Foundation.
• (2004) Prix d'excellence. Université de Montréal.
• (2004) Prix Hans Haley - best presentation. Club de Recherches Cliniques du Québec.
• (2004) Prix Jean-Louis Levesques. Montreal Heart Institute.
• (2003) Doctoral Award. FRQS.

Financement

• Subvention. Regulation of macrophage activation, infiltration and chronic inflammation by MKP-2. Canadian Institutes of Health Research (Ottawa, Canada). 100 000 $. (2024-2025).
  Numéro de subvention : 202403PJ9. Voir plus
• Subvention. Macrophage polarization and phosphatase in diabetic kidney disease. Diabetes Canada (Toronto, Canada). Operating grant. 300 000 $. (2023-2026).
• Subvention. Lutter contre les complications du diabete pour la sante. Canadian Institutes of Health Research (Ottawa, Canada). 5 500 $. (2023-2024).
  Numéro de subvention : 202303SC8. Voir plus
• Subvention. Role of the apelinergic system in peripheral arterial disease in diabetes. Canadian Institutes of Health Research (Ottawa, Canada). 979 200 $. (2022-2027).
  Numéro de subvention : 202203PJT. Voir plus
• Subvention. Electron microscopy platform to study kidney pathologies, chronic pain and nanoparticule structure. Canada Foundation for Innovation (Ottawa, Canada). 404 699 $. (2022).
  Numéro de subvention : 43248. Voir plus
• Subvention. The Developmental Origins of Pediatric Type 2 Diabetes and Early Renal Dysfunction. Canadian Institutes of Health Research (Ottawa, Canada). 1 526 553 $. (2022-2026).
  Numéro de subvention : 202107DT4. Voir plus
• Subvention. The Developmental Origins of Pediatric Type 2 Diabetes and Early Renal Dysfunction. Canadian Institutes of Health Research (Ottawa, Canada). 10 000 $. (2021-2022).
  Numéro de subvention : 202012DL4. Voir plus
• Subvention. Center of Excellence of the Université de Sherbrooke in Diabetes, Obesity and Cardiovascular Complications (CEUSDOCC). Université de Sherbrooke (Sherbrooke, Canada). 163 000 $. (2020-2026).
• Subvention. Phosphatases and mechanisms of poor collateral vessel formation in diabetes. Canadian Institutes of Health Research (Ottawa, Canada). 769 244 $. (2018-2023).
  Numéro de subvention : 201803PJT. Voir plus
• Subvention. Role of IGFBP-2 on podocyte injury and type 2 diabetic nephropathy. FRQS (Montreal, Canada). Intercenter grant. 40 000 $. (2018-2020).
• Subvention. Vascular Complication of Diabetes. Canadian Institutes of Health Research (Ottawa, Canada). 500 000 $. (2017-2022).
  Numéro de subvention : 201704CRC. Voir plus
• Subvention. Mechanisms of insulin resistance in podocytes and diabetic nephropathy. Canadian Institutes of Health Research (Ottawa, Canada). 691 147 $. (2017-2022).
  Numéro de subvention : 201610PJT. Voir plus
• Subvention. Evaluation of SHP-1 expression in podocyturia of diabetic patients. Foundation diabetes Brome-Missisquoi (Bedford, Canada). 50 000 $. (2016-2020).
• Subvention. New mechanisms of podocyte dysfunction in diabetic nephropathy. Breakthrough T1D (New York, États-Unis). 110 000 USD. (2015-2016).
  Numéro de subvention : 1-INO-2015-135-A-N. Voir plus
• Subvention. New mechanisms of podocyte injury in diabetic nephropathy. Canadian Institutes of Health Research (Ottawa, Canada). 100 000 $. (2015-2016).
  Numéro de subvention : 201505MOP. Voir plus
• Subvention. Mechanisms of diabetes-induced insulin resistance in podocytes. Kidney Foundation of Canada (Montreal, Canada). Biomedical Grant. 100 000 $. (2015-2017).
• Subvention. Etude in vivo de l'effet de l'age sur les mecanismes de regulation du transport inverse du cholesterol: Impact sur le developpement de l'atherosclerose. Canadian Institutes of Health Research (Ottawa, Canada). 100 000 $. (2014-2015).
  Numéro de subvention : 201309IAO. Voir plus
• Subvention. Live-cell perfusion imaging to study vascular complications of diabetes. Canada Foundation for Innovation (Ottawa, Canada). 92 032 $. (2013).
  Numéro de subvention : 32327. Voir plus
• Subvention. Role of SHP-1 in poor collateral vessel formation and angiogenic response in diabetes. Canadian Institutes of Health Research (Ottawa, Canada). 610 571 $. (2013-2018).
  Numéro de subvention : 201303MOP. Voir plus
• Subvention. Mechanisms for podocyte injury and diabetic nephropathy. Canadian Institutes of Health Research (Ottawa, Canada). 100 000 $. (2013-2014).
  Numéro de subvention : 201209PNI. Voir plus
• Subvention. Diabetes and Vascular Complications. Canadian Institutes of Health Research (Ottawa, Canada). 500 000 $. (2012-2017).
  Numéro de subvention : 201204CRC. Voir plus
• Subvention. Insulin actions in podocyte injury associated to diabetic nephropathy. Breakthrough T1D (New York, États-Unis). 55 000 USD. (2012-2014).
  Numéro de subvention : 27-2012-531. Voir plus
• Subvention. Role of PKC delta in PDGF and VEGF inhibition causing poor collateral vessel formation in diabetes. Canadian Diabetes Association (Toronto, Canada). Operating Grant. 228 205 $. (2010-2013).
• Subvention. Role of PKC and SHP-1 in podocyte apoptosis and diabetic nephropathy. Kidney Foundation of Canada (Montreal, Canada). Biomedical Grant. 100 000 $. (2010-2012).
• Subvention. Rôle de PKC delta et de SHP-1 dans la régulation des voies de signalisation du PDGF et EGF impliqué dans les complications vasculaires chez les diabétiques. Fonds de Recherche du Québec - Santé (Montreal, Canada). 45 000 $. (2009-2010).
  Numéro de subvention : 17222. Voir plus
• Subvention. Role of SHP-1 regulating PDGF and EGF actions in diabetic complications. Breakthrough T1D (New York, États-Unis). 264 047 USD. (2009-2012).
  Numéro de subvention : 10-2009-245. Voir plus
• Subvention. Role of PKC, oxidation and p38 on glucose action of pericytes apoptosis. Breakthrough T1D (New York, États-Unis). 91 772 USD. (2007-2009).
  Numéro de subvention : 3-2007-169. Voir plus

Publications

Articles

• (2025). Acute Effect of High-Intensity Interval Exercise on Blood Pressure in Females Living with Type 2 Diabetes and Hypertension. MEDICINE & SCIENCE IN SPORTS & EXERCISE. DOI
• (2025). Current advances in protein phosphatases in kidney disease. CURRENT OPINION IN PHYSIOLOGY. DOI
• (2025). Endothelial SHP-1 regulates diabetes-induced abnormal collateral vessel formation and endothelial cell senescence. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY. DOI
• (2024). Losartan and metabolite EXP3179 activate endothelial function without lowering blood pressure in AT2 receptor KO mice. EUROPEAN JOURNAL OF PHARMACOLOGY. DOI
• (2023). Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb. FRONTIERS IN CARDIOVASCULAR MEDICINE. DOI
• (2023). Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease. KIDNEY INTERNATIONAL. DOI
• (2023). Tungsten toxicity on kidney tubular epithelial cells induces renal inflammation and M1-macrophage polarization. CELL BIOLOGY AND TOXICOLOGY. DOI
• (2022). Enhanced SHP-1 Expression in Podocyturia Is Associated with Kidney Dysfunction in Patients with Diabetes. KIDNEY360. DOI
• (2022). Reduction of DUSP4 contributes to podocytes oxidative stress, insulin resistance and diabetic nephropathy. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. DOI
• (2022). Transcriptomic modulation in response to high-intensity interval training in monocytes of older women with type 2 diabetes. EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY. DOI
• (2021). Diabetes Impaired Ischemia-Induced PDGF (Platelet-Derived Growth Factor) Signaling Actions and Vessel Formation Through the Activation of Scr Homology 2-Containing Phosphatase-1. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. DOI
• (2021). Endothelial deletion of PKCδ prevents VEGF inhibition and restores blood flow reperfusion in diabetic ischemic limb. DIABETES & VASCULAR DISEASE RESEARCH. DOI
• (2021). Fish oil replacement prevents, while docosahexaenoic acid-derived protectin DX mitigates end-stage-renal-disease in atherosclerotic diabetic mice. FASEB JOURNAL. DOI
• (2021). Growth Factor Deregulation and Emerging Role of Phosphatases in Diabetic Peripheral Artery Disease. FRONTIERS IN CARDIOVASCULAR MEDICINE. DOI
• (2020). Ablation of angiotensin type 2 receptor prevents endothelial nitric oxide synthase glutathionylation and nitration in ischaemic abductor muscle of diabetic mice. DIABETES & VASCULAR DISEASE RESEARCH. DOI
• (2020). Saturated fatty acids induce insulin resistance in podocytes through inhibition of IRS1 via activation of both IKKβ and mTORC1. SCIENTIFIC REPORTS. DOI
• (2019). Calcifediol Decreases Interleukin-6 Secretion by Cultured Human Trophoblasts From GDM Pregnancies. JOURNAL OF THE ENDOCRINE SOCIETY. DOI
• (2019). Diabetes-Induced DUSP4 Reduction Promotes Podocyte Dysfunction and Progression of Diabetic Nephropathy. DIABETES. DOI
• (2019). Mice lacking angiotensin type 2 receptor exhibit a sex-specific attenuation of insulin sensitivity. MOLECULAR AND CELLULAR ENDOCRINOLOGY. DOI
• (2018). Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. SCIENTIFIC REPORTS. DOI
• (2018). Protein phosphatases and podocyte function. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION. DOI
• (2017). Deletion of AT2 Receptor Prevents SHP-1-Induced VEGF Inhibition and Improves Blood Flow Reperfusion in Diabetic Ischemic Hindlimb. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. DOI
• (2016). Biomarker analysis of Fabry disease patient cell fractions using tandem mass spectrometry. MOLECULAR GENETICS AND METABOLISM. DOI
• (2016). Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes. DIABETES. DOI
• (2015). Increased SHP-1 Protein Expression by High Glucose Levels Reduces Nephrin Phosphorylation in Podocytes. JOURNAL OF BIOLOGICAL CHEMISTRY. DOI
• (2015). PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis. CARDIOVASCULAR RESEARCH. DOI
• (2013). Expression of SHP-1 induced by hyperglycemia prevents insulin actions in podocytes. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. DOI
• (2013). PKCδ Impaired Vessel Formation and Angiogenic Factor Expression in Diabetic Ischemic Limbs. DIABETES. DOI
• (2012). Glomerular VEGF resistance induced by PKCβ/SHP-1 activation and contribution to diabetic nephropathy. FASEB JOURNAL. DOI
• (2012). Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes. DIABETES. DOI
• (2011). Glomerular-specific protein kinase C-β-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. KIDNEY INTERNATIONAL. DOI
• (2010). Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications. CIRCULATION RESEARCH. DOI
• (2010). Correlation of Vascular Complications with SHP-1 Expression in Patients with More Than 50 Years of Diabetes. DIABETES.
• (2010). Loss of Insulin Signaling in Vascular Endothelial Cells Accelerates Atherosclerosis in Apolipoprotein E Null Mice. CELL METABOLISM. DOI
• (2009). Activation of PKC-δ and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. NATURE MEDICINE. DOI
• (2009). p38 MAPK Is a Major Regulator of MafA Protein Stability under Oxidative Stress. MOLECULAR ENDOCRINOLOGY. DOI
• (2008). Local Delivery of 17-Beta-Estradiol Modulates Collagen Content in Coronary Porcine Arteries after PTCA and Stent Implantation. JOURNAL OF VASCULAR RESEARCH. DOI
• (2008). Selective Regulation of Heme Oxygenase-1 Expression and Function by Insulin through IRS1/Phosphoinositide 3-Kinase/Akt-2 Pathway. JOURNAL OF BIOLOGICAL CHEMISTRY. DOI
• (2007). Glypican 4, a membrane binding protein for bactericidal/permeability-increasing protein signaling pathways in retinal pigment epithelial cells. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. DOI
• (2006). Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects. FASEB JOURNAL. DOI
• (2006). Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion:: An ERα-mediated pathway. CARDIOVASCULAR RESEARCH. DOI
• (2003). Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. CIRCULATION RESEARCH. DOI
• (2002). Estrogen regulation of endothelial and smooth muscle cell migration and proliferation - Role of p38 and p42/44 mitogen-activated protein kinase. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. DOI

Propriétés intellectuelles

Brevets

• Methods of Modulating Metabolic Memory. (2007).

Autres contributions

Cours enseignés à l'UdeS

• BCM606 - Endocrinologie moléculaire. (2025-2026). (2CR).
• PHS712 - Endocrinologie cellulaire et moléculaire. (2024, 2026). (2CR).
• PHS713 - Hypertension et hormones. (2025). (2CR).
• END506 - Éléments d'endocrinologie moléculaire. (2023). (3CR).

Présentations

• (2025). Phosphatase and new targets to treat kidney and peripheral artery disease in diabetes. Beth Israel Deaconess Medical Center - invited speaker.
• (2025). Vascular complications of diabetes. Diabetes Canada Annual Conferences.
• (2025). SUMOylation in diabetic kidney disease. Kidney Week of the American Society of Nephrology.
• (2024). Regulation of fibrosis by phosphatase in diabetic kidney disease. Diabetes Canada annual conference.
• (2023). New mechanisms of diabetic kidney disease. Dream symposium.
• (2023). Angiotensine receptor type 2 in vascular complications of diabetes. Advanced Angiotensin Therapeutics Network.
• (2023). Diabetic kidney disease and protecting factors. Quebec Arterial Hypertensive Society.
• (2022). Phosphatase action and diabetic kidney disease. Huashan Diabetes and its Complication Forum.
• (2022). SHP-1 in endothelial cell senescence in diabetes. Vascular Discovery: From Genes to Medicine 2022.
• (2021). Phosphatase, insulin resistance and chronic kidney disease. MUCH endocrin conference.
• (2021). Peripheral arterial disease in diabetes: where do we stand?. Diabetes Canada Annual Conference.
• (2021). Phosphatases, insulin resistance and diabetic nephropathy. M3K - Canadian Kidney Conference.
• (2020). New treatment strategies to prevent peripheral arterial disease in diabetes. Canadian Vascular and Lipid Summit.
• (2019). The role of phosphatases in diabetic renal disease. HMR Seminar Series.
• (2019). Role of phosphatase in peripheral arterial and chronic kidney diseases in diabetes. CardioMetabolic, Diabetes and Obesity Annual Meeting.
• (2017). Mechanisms of insulin resistance in podocytes and diabetic nephropathy. CRCHUM - MUHC Nephrology Conference.
• (2017). Protecting factor inhibition and vascular complications of diabetes. Indiana University School of Public Health-Bloomington.
• (2016). Essentials for Preparing a Career in Diabetes and Endocrine Research. CDA/CSEM Professional Conference.
• (2016). Vascular complication of diabetes. Signalisation Québec 2016.
• (2013). Glycemic memory in diabetic nephropathy: the quest to find new mechanisms. CHUM-MUHC Nephrology Conference.
• (2013). Insulin regulation in podocytes and diabetic nephropathy. University of Toronto CityWide Endocrine Rounds.
• (2013). Targeting Protein Kinase C in the vessel wall: new perspectives. 2e symposium Cardiometabolic Risk and Vascular Diseases -- from Mechanisms to Treatment.
• (2013). Diabetes and cardiovascular complications: the quest to find new markers. Conference series - Montreal Heart Institute.
• (2013). Inhibition of the Protecting Factors: New Mechanism of Vascular Complications in Diabetes. IRCM Cardiometabolite Disease Seminar Series.
• (2013). New Mechanisms for metabolic legacy effect in diabetic nephropathy. Kidney Research Centre (KRC) Journal Club rounds.
• (2013). Vascular complications of diabetes: why there is no treatment yet?. BioMed Research Center.
• (2011). Diabetes and Vascular Complications: Beyond Oxidative Stress. Endocrinology/Nutrition/Renal Diseases.
• (2010). Hyperglycemia-induced apoptosis -- a NF-?B independent pathway. Signalisation Quebec 2010.